Table 1 Summary of clinical studies evaluating tucatinib or its combination with other agents in HER2+ metastatic breast cancer patients
From: The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
Treatment(s) | Other factor(s) | Study design and finding(s) |
|---|---|---|
Tucatinib [65] | – | To determine the MTD, antitumor activity, and pharmacokinetic properties of tucatinib The tucatinib MTD was determined to be 600 mg twice daily; 22% of patients treated at the MTD had a partial response + SD |
Tucatinib + trastuzumab + capecitabine [33] | ALT/AST | To evaluate the therapeutic responses of tucatinib vs. placebo combination with trastuzumab and capecitabine Tucatinib-combination resulted in improved PFS and increased OS with common adverse events compared to the placebo-combination group |